Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder : A Narrative Review of Available Clinical Evidence.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing preclinical, observational, and trial data without systematic review or meta-analysis methodology.
PubMed 42486217 · doi:10.1016/j.biopsych.2026.07.010
What was done
This narrative review synthesized preclinical experiments (in mice, rats, and nonhuman primates), large registry studies, target trial emulation analyses, real-world observational data, case reports, and randomized controlled trials (RCTs) evaluating glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of alcohol use disorder (AUD) and reduced alcohol consumption.
What was found
The abstract reports no numerical data or effect sizes. It notes that only 3 RCTs have evaluated GLP-1RAs in AUD so far, which showed reductions in alcohol cue brain reactivity and alcohol intake, especially in individuals with overweight or obesity. Observational, registry, real-world, and case report data similarly showed consistent associations between GLP-1RA use and reduced alcohol consumption and craving, alongside proposed mechanisms including reward circuitry modulation, incentive salience, gastric emptying, and metabolic signaling.
Why it matters
Pharmacological treatment options for AUD are limited; these findings highlight GLP-1RAs as a mechanistically novel candidate therapy that warrants dedicated clinical trials.
Limits
The paper is a narrative review rather than a systematic review or meta-analysis. Clinical trial evidence is limited to only 3 RCTs, and patient sample sizes, treatment durations, and specific effect estimates are not provided in the abstract. Observational and registry data carry risks of residual confounding, and efficacy in individuals without overweight or obesity remains unclear.
Cited by
- supports GLP-1 receptor agonists slow gastric emptying, causing ingested alcohol to remain in the stomach longer.